<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04035200</url>
  </required_header>
  <id_info>
    <org_study_id>OAG2002</org_study_id>
    <nct_id>NCT04035200</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability and Efficacy Study of V117957 in Subjects With Insomnia Associated With Alcohol Cessation</brief_title>
  <official_title>A Phase 2, Randomized, Double-Blind, Multi-Center, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety, Tolerability, and Efficacy of V117957 in Subjects With an Alcohol Use Disorder Who Are Experiencing Insomnia Associated With Alcohol Cessation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Imbrium Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Imbrium Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability and efficacy of V117957 in
      subjects with alcohol use disorder (AUD) who experience insomnia associated with alcohol
      cessation, compared to placebo.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 23, 2019</start_date>
  <completion_date type="Anticipated">August 2020</completion_date>
  <primary_completion_date type="Anticipated">August 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline of wakefulness after sleep onset (WASO) measured by polysomnography (PSG)</measure>
    <time_frame>Baseline, Day 2, Day 21</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in mean sleep efficiency (SE)</measure>
    <time_frame>Baseline, Day 2, Day 21</time_frame>
    <description>Sleep component as measured by PSG</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in mean latency to persistent sleep (LPS)</measure>
    <time_frame>Baseline, Day 2, Day 21</time_frame>
    <description>Sleep component as measured by PSG</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in mean total sleep time (TST)</measure>
    <time_frame>Baseline, Day 2, Day 21</time_frame>
    <description>Sleep component as measured by PSG</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in mean number of awakenings (NAW)</measure>
    <time_frame>Baseline, Day 2, Day 21</time_frame>
    <description>Sleep component as measured by PSG</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in subjective sleep quality (sSleep)</measure>
    <time_frame>Baseline, Day 7, Day 14, Day 21</time_frame>
    <description>Self-reported sleep outcome measured by subject diary data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in subjective total sleep time (sTST)</measure>
    <time_frame>Baseline, Day 7, Day 14, Day 21</time_frame>
    <description>Self-reported sleep outcome measured by subject diary data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in subjective wakefulness after sleep onset (sWASO)</measure>
    <time_frame>Baseline, Day 7, Day 14, Day 21</time_frame>
    <description>Self-reported sleep outcome measured by subject diary data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in subjective sleep onset latency (sSOL)</measure>
    <time_frame>Baseline, Day 7, Day 14, Day 21</time_frame>
    <description>Self-reported sleep outcome measured by subject diary data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in subjective time in bed (sTIB)</measure>
    <time_frame>Baseline, Day 7, Day 14, Day 21</time_frame>
    <description>Self-reported sleep outcome measured by subject diary data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in subjective sleep efficiency (sSE)</measure>
    <time_frame>Baseline, Day 7, Day 14, Day 21</time_frame>
    <description>Self-reported sleep outcome measured by subject diary data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in subjective number of awakenings (sNAW)</measure>
    <time_frame>Baseline, Day 7, Day 14, Day 21</time_frame>
    <description>Self-reported sleep outcome measured by subject diary data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in subjective morning sleepiness on awakening</measure>
    <time_frame>Baseline, Day 7, Day 14, Day 21</time_frame>
    <description>Self-reported sleep outcome measured by subject diary data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of responders to V117957 1 mg and 2 mg compared to placebo</measure>
    <time_frame>Day 28 (End of Study)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of rebound insomnia during the Washout/Follow-up Period</measure>
    <time_frame>Day 22 up to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Next day residual effects as determined by Digit Symbol Substitution Test (DSST)</measure>
    <time_frame>Baseline, Day 2, Day 21</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Next day residual effects as determined by Karolinska Sleepiness Scale (KSS)</measure>
    <time_frame>Baseline, Day 2, Day 21</time_frame>
    <description>The KSS is a 9-point Likert scale (range: 1 = &quot;extremely alert&quot; to 9 = &quot;very sleepy&quot;) that measures sleepiness</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Next day residual effects as determined by Profile of Mood States (POMS) - Brief</measure>
    <time_frame>Baseline, Day 2, Day 21</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Insomnia</condition>
  <arm_group>
    <arm_group_label>V117957 1 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>V117957 tablets taken orally at bedtime</description>
  </arm_group>
  <arm_group>
    <arm_group_label>V117957 2 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>V117957 tablets taken orally at bedtime</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo to match V117957 tablets taken orally at bedtime</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>V117957 tablets</intervention_name>
    <description>V117957 tablets taken orally at bedtime</description>
    <arm_group_label>V117957 1 mg</arm_group_label>
    <arm_group_label>V117957 2 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Tablets to match V117957</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria include:

          -  Male or female, 18-64 years of age with a body weight of 50-100 kg (110-220 lbs) and a
             body mass index (BMI) of 18-32 kg/m2.

          -  Otherwise healthy as determined by medical evaluation that includes: medical history,
             physical examination, neurological exam, laboratory tests, vital signs, and cardiac
             monitoring.

          -  History of moderate or severe alcohol use disorder (AUD) categorized based on
             Diagnostic and Statistical Manual of Mental Disorders Fifth Edition (DSM-5) criteria,
             as follows:

               -  Moderate as defined by presence of 4-5 of the 11 criteria

               -  Severe as defined by the presence of â‰¥ 6 of the 11 criteria.

          -  At least 3 weeks and not more than 6 months since last alcoholic beverage intake at
             the time of study screening. Any subject who completed an alcohol detoxification
             program must be at least 7 days from completion of the program at the time of
             screening.

          -  Persistent insomnia that emerged or worsened during AUD period, or during or after
             alcohol cessation characterized by a study-specific sleep diary.

          -  A female participant is eligible to participate if she is not pregnant and not
             breastfeeding. Both females of childbearing potential and nonsurgically sterilized
             males with a sexual partner of childbearing potential must be willing to use adequate
             and reliable contraception throughout the study.

          -  Willing to refrain from a behavioral or other treatment program for insomnia during
             participation in the study.

        Key Exclusion Criteria include:

          -  Current diagnosis of a sleep-related breathing disorder including obstructive sleep
             apnea (with or without continuous positive airway pressure (CPAP) treatment), periodic
             limb movement disorder, restless legs syndrome, circadian rhythm sleep disorder or
             narcolepsy.

          -  An apnea-hypopnea index (AHI) score of &gt;10 or a periodic limb movement arousal index
             (PLMAI) score of &gt; 15 recorded during the screening period PSG.

          -  Documented history of insomnia prior to onset of the alcohol use disorder (AUD), which
             did not worsen during the AUD period or during or after alcohol cessation.

          -  Comorbid conditions which interfere with normal sleep pattern or the evaluation of
             next day residual effects.

          -  Any lifetime history of suicidal ideation or behavior.

          -  History of or any current conditions that might interfere with drug absorption,
             distribution, metabolism, or excretion (including any surgical interventions for
             weight loss).

          -  Any history of seizures (except related to alcohol withdrawal) or head trauma with
             sequelae.

          -  Known history of testing positive for human immunodeficiency virus (HIV), hepatitis B
             surface antigen (HBsAg) or hepatitis C antibody (anti-HCV).

          -  History of diagnosed, active liver disease or elevated liver enzymes/bilirubin.

          -  History of kidney stones or renal insufficiency or abnormal kidney function at
             screening.

          -  Uncontrolled hypertension (&gt; 140 mm Hg systolic / 90 mm Hg diastolic).

          -  Use of any medication that affects sleep and/or wake function during the week before
             starting the screening period.

          -  Subjects currently undergoing treatment of other addictions in addition to alcohol.

          -  Excessive caffeine consumption.

          -  Positive urine drug screen for prohibited substances, except for cannabis on a
             case-by-case basis.

          -  History of drug use disorder over the past year, other than
             alcohol/nicotine/caffeine/cannabis.

          -  Plans to travel across more than 3 time zones in the 2 weeks before screening, or
             during study participation.

          -  Night or rotating shift worker.

          -  Any history and/or current evidence of other medical (eg, cardiac, respiratory,
             gastrointestinal, renal, malignancy other than basal cell carcinoma), neurological, or
             psychiatric conditions that, in the opinion of the investigator, could affect the
             subject's safety or interfere with the study.

        Other protocol-specific inclusion/exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Scott Smith</last_name>
    <phone>512-913-6731</phone>
    <email>Scott.Smith@ppdi.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>California Clinical Trials Medical Group</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91206</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Artemis Institute for Clinical Research</name>
      <address>
        <city>Riverside</city>
        <state>California</state>
        <zip>92503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Artemis Institute for Clinical Research</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CITrials</name>
      <address>
        <city>Santa Ana</city>
        <state>California</state>
        <zip>92705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>SDS Clinical Trials, Inc.</name>
      <address>
        <city>Santa Ana</city>
        <state>California</state>
        <zip>92705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Francis Medical Institute</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33765</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Centers of America</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Innovative Clinical Research, Inc.</name>
      <address>
        <city>Miami Lakes</city>
        <state>Florida</state>
        <zip>33016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Centers of America, LLC</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NeuroMedical Research Institute</name>
      <address>
        <city>Panama City</city>
        <state>Florida</state>
        <zip>32405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>NeuroTrials Research Inc</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30328</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Chevy Chase</city>
        <state>Maryland</state>
        <zip>20815</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sleep Disorders Centers of the Mid Atlantic</name>
      <address>
        <city>Glen Burnie</city>
        <state>Maryland</state>
        <zip>21061</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wake Research - Clinical Research Center of Nevada, LLC</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>SPRI Clinical Trials</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11235</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinilabs Drug Development Corporation</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10019</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CTI Clinical Research Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>SleepMed West Ashley</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29407</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Advanced Medical Trials</name>
      <address>
        <city>Georgetown</city>
        <state>Texas</state>
        <zip>78628</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 25, 2019</study_first_submitted>
  <study_first_submitted_qc>July 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 29, 2019</study_first_posted>
  <last_update_submitted>July 10, 2020</last_update_submitted>
  <last_update_submitted_qc>July 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Initiation and Maintenance Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

